CSV March 29, 2022 through March 29, 2024 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
IPRATROPIUM IMPURITIES		*USPNF Online*	Online	29-Mar-2024	1-Apr-2024	*NA*	*NA*	In *Organic*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
BROMIDE INHALATION SOLUTION								*Impurities*: Change **Column:** 4.6-mm × 25-µm; 5-µm packing L1 to: **Column:** 4.6-mm × 25-cm; 5-µm packing L1
SUCROSE	IMPURITIES	*USPNF Online*	Online	29-Mar-2024	1-Apr-2024	*NA*	*NA*	In *Sulfite/ Analysis*/footnote 1: Change Test kit for sulfite determination may be ordered from the following suppliers: Megazyme Ltd. (Product code: K-ETSULPH); R-Biopharm (Enzytec) (Article No.: E6275); BioSen Tec/Nzytech

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(Catalogue No.: AK00071). to: Test kit for sulfite determination may be ordered from the following suppliers: Megazyme Ltd. (Product code K-ETSULPH); R-Biopharm (Enzytec) (Article No. E6275); Nzytech (Catalogue No. AK00071) and BioSenTec (Product reference 040-E).
LIDOCAINE	ASSAY	*USPNF Online*	Online	29-Mar-2024	1-Apr-2024	*NA*	*NA*	In *Procedure*: Change **Column:** 3.9-mm × 30-cm; 4-µm packing L1 to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ENSULIZOLE	IDENTIFICATION	*USPNF Online*	Online	29-Mar-2024	1-Apr-2024	*NA*	*NA*	**Column:** 3.9-mm × 30-cm; 10-µm packing L1 In *B*.: Change The retention time of the major peak of the *Sample solution* exhibits maxima and minima at the same wavelengths as those of the *Standard solution*, as obtained in the *Assay*. to: The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LIDOCAINE, RACEPINEPHRINE AND TETRACAINE HYDROCHLORIDES COMPOUNDED TOPICAL GEL	DEFINITION	*USPNF Online*	Online	29-Mar-2024	1-Apr-2024	*NA*	*NA*	Change Prepare Lidocaine, Racepinephrine, and Tetracaine Hydrochlorides Compounded Topical Gel containing 40 mg/mL of lidocaine hydrochloride, 1 mg/mL of racepinephrine hydrochloride, and 10 mg/mL of tetracaine hydrochloride as follows (see *Pharmaceutical Compounding—Sterile Preparations* <797>). to: Prepare Lidocaine, Racepinephrine, and Tetracaine Hydrochlorides

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Compounded Topical Gel containing 40 mg/mL of lidocaine hydrochloride, 1 mg/mL of racepinephrine hydrochloride, and 10 mg/mL of tetracaine hydrochloride as follows (see *Pharmaceutical Compounding—Nonsterile Preparations* <795>).
METHYLNALTREXONE BROMIDE	CHEMICAL INFORMATION	*USPNF Online*	Online	23-Feb-2024	1-Mar-2024	*NA*	*NA*	Correct the chemical structure
IODIXANOL INJECTION	IMPURITIES	*USPNF Online*	Online	23-Feb-2024	1-Mar-2024	*NA*	*NA*	In *Organic Impurities, Procedure 2*/footnote 4: Change 5-[[3-[[3-[[[3-[[3-[[3,5-Bis-[[[2,3-dihydroxypropyl]amino]carbonyl]-2,4,6-triiodoph

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								enyl](acetylimino)]-2-hydroxypropyl](acetylimino)]-5-[[[2,3-dihydroxypropyl]amino]carbonyl]-2,4,6-triiodophenyl]carbonyl]amino]-2-hy droxypropyl]oxy]-2-hydroxypropyl](acetylimino)]-*N*,*N*'-bis(2,3-dihy dr oxypropyl)-2,4,6-triiodo-1,3-benzendicarboxamide. to: 5-[[3-[[3-[[[3-[[3-[[3,5-Bis-[[[2,3-dihydroxypropyl]amino]carbonyl]-2,4,6-triiodophenyl](acetylamino)]-2-hydroxypropyl](acetylamino)]-5-[[[2,3-dihydroxypropyl]amino]carbonyl]-2,4,6-triiodophenyl]carbonyl]amino]

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-2-hydroxypropyl]oxy]-2-hydroxypropyl](acetylamino)]-*N*,*N*'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide.
THALIDOMIDE CAPSULES	ASSAY	*USPNF Online*	Online	23-Feb-2024	1-Mar-2024	*NA*	*NA*	In *Procedure*: Change $1000C(R_U/R_S)$ to: $500C(R_U/R_S)$
COCOYL CAPRYLOCAPRATE	SPECIFIC TESTS	*USPNF Online*	Online	23-Feb-2024	1-May-2024	*NA*	*NA*	In *Fats and Fixed Oils* ?401?, *Procedures*, *Hydroxyl Value*/*Analysis*: Change Calculate the acid value as directed in the chapter. to: Calculate the hydroxyl value as directed in the chapter.
METOLAZONE	IMPURITIES	*USPNF Online*	Online	23-Feb-2024	1-Mar-2024	*NA*	*NA*	In *Organic*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
IODIXANOL INJECTION	ADDITIONAL REQUIREMENTS	*USPNF Online*	Online	23-Feb-2024	1-Mar-2024	*NA*	*NA*	*Impurities/Chromatographic system/Column*: Change 4.6-mm × 25-cm; 5-µm packing 1 to: 4.6-mm × 25-cm; 5-µm packing L1 In *USP Reference Standards* ?11?/USP Iodixanol Related Compound ERS: Change 5-[[3-[[3-[[(2,3-Dihydroxypropyl)amino]carbonyl]-5- [[amino]carbonyl]-2,4,6-triiodophenyl](acetylimino)]-2-hydroxypropyl]-(acetylimino)]-N,N?-bis(2,3-dihydroxypr

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								opyl)-2,4,6-triiodo-1,3-benzenedicarboxamide. to: 5-{*N*-[3-(*N*-{3-Carbamoyl-5-[(2,3-dihydroxypropyl)carbamoyl]-2,4,6-triiodophenyl}acetamido)-2-hydroxypropyl]acetamido}-N^1,N^3-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide.
FLURAZEPAM HYDROCHLORIDE	USP REFERENCE STANDARDS ?11?	*USPNF Online*	Online	23-Feb-2024	1-Mar-2024	*NA*	*NA*	In USP Flurazepam Related Compound C RS: Change 5-Chloro-2-(2-diethylaminoethyl(amino)-2?-fluorobenzophenone hydrochloride. to: 5-Chloro-2-(2-diethylaminoethylamino)-2?-fluor

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								obenzophenone hydrochloride.
PROPOFOL	ASSAY	*USPNF Online*	Online	23-Feb-2024	1-Mar-2024	*NA*	*NA*	In *Procedure 2*/*Mobile phase*: Change Hexane, acetonitrile, and alcohol (990: 7.5: 1) to: Hexane, acetonitrile, and alcohol, absolute (990: 7.5: 1)
DICYCLOMINE HYDROCHLORIDE	IDENTIFICATION	*USPNF Online*	Online	26-Jan-2024	1-Feb-2024	*NA*	*NA*	In *B. Identification Tests—General* ?191?, *Chemical Identification Tests*, *Chloride*: Change Meets the requirements when tested as specified in test *B*. to: Meets the requirements of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
AMOXICILLIN ORAL SUSPENSION	IDENTIFICATION	*USPNF Online*	Online	26-Jan-2024	1-Feb-2024	*NA*	*NA*	the test for amine hydrochlorides Change Shake a portion of Oral Suspension with a mixture of acetone and 0.1 N hydrochloric acid (4:1) to obtain a solution containing about 1 mg of amoxicillin per mL. The solution responds to the *Identification* test under *Amoxicillin Capsules*. to: Prepare a test solution by shaking a portion of Oral Suspension with a mixture

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								of acetone and 0.1 N hydrochloric acid (4:1) to obtain a solution containing about 1 mg of amoxicillin per mL. Prepare a Standard solution of USP Amoxicillin RS in 0.1 N hydrochloric acid containing 1 mg per mL. Use within 10 minutes after preparation. Apply separately 5 µL of each solution on a thin-layer c hromatographic plate coated with a 0.25-mm layer of chromat ographic silica gel mixture (see *Chromatograph*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								y ?621?). Place the plate in a suitable chromatographic chamber, and develop the chromatogram in a solvent system consisting of a mixture of methanol, chloroform, water, and pyridine (90:80:30:10). When the solvent front has moved about three-fourths of the length of the plate, remove the plate from the chamber, and dry with warm air for 10 minutes. Locate the spots on the plate by spraying lightly

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								with a solution of ninhydrin in alcohol containing 3 mg per mL, and dry at 110° for 15 minutes: the R_F value of the principal spot obtained from the test solution corresponds to that obtained from the Standard solution.
LINEZOLID TABLETS	PERFORMANCE TESTS	*USPNF Online*	Online	26-Jan-2024	1-Feb-2024	*NA*	*NA*	In *Dissolution* ?711?/*Test 1*/*Analysis*: Change Result = $(r_U/r_S) \times C_S \times V \times (1/L) \times 100$ r_U = peak response of linezolid from the *Sample solution* r_S = peak response of linezolid from

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the *Standard solution* C_S = concentration of USP Linezolid RS in the *Standard solution* (mg/mL) *V* = volume of *Medium*, 900 mL *L* = label claim (mg/Tablet) to: Result = $(r_U/r_S) \times C_S \times V \times (1/L) \times D \times 100$ r_U = peak response of linezolid from the *Sample solution* r_S = peak response of linezolid from the *Standard solution* C_S = concentration of USP Linezolid

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								RS in the *Standard solution* (mg/mL) *V* = volume of *Medium*, 900 mL *L* = label claim (mg/Tablet) *D* = dilution factor of the *Sample solution*, as needed
CARVEDILOL TABLETS	PERFORMANCE TESTS	*USPNF Online*	Online	26-Jan-2024	1-Feb-2024	*NA*	*NA*	In *Dissolution* <711>/*Test 3*/*Chromatographic system*/*Column*: Change 4.6-mm × 15-mm; 5-?m packing L7 to: 4.6-mm × 15-cm; 5-?m packing L7
THEOPHYLLINE CAPSULES	IDENTIFICATION	*USPNF Online*	Online	26-Jan-2024	1-Feb-2024	*NA*	*NA*	Change **A:** The contents of the Capsules

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								respond to *Identification* tests *A* and *B* under *Theophylline Tablets*. **B:** The retention time of the major peak in the chromatogram of the *Assay preparation* corresponds to that in the chromatogram of the *Standard preparation*, as obtained in the *Assay*. to: **A:** Triturate a quantity of the contents of Capsules, equivalent to about 500 mg of theophylline, with 10-mL and 5-mL portions of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solvent hexane, and discard the solvent hexane. Triturate the residue with two 10-mL portions of a mixture of equal volumes of 6 N ammonium hydroxide and water, and filter each time. Evaporate the combined filtrates to about 5 mL, neutralize, if necessary, with 6 N acetic acid, using litmus, and then cool to about 15°, with stirring. Collect the precipitate on a filter, wash it with cold water, and dry at 105° for 2 hours: the theophylline so

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								obtained melts between 270° and 274° (see *Melting Range or Temperature* ?741?, *Procedures*, *Procedure for Class I*). Retain the remaining portion of the theophylline for use in *Identification* test *B*. **B:** The IR absorption spectrum of a potassium bromide dispersion of the residue obtained in *Identification* test *A* exhibits maxima only at the same wavenumbers as that of a potassium bromide

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								dispersion of USP Theophylline RS. **C:** The retention time of the major peak in the chromatogram of the *Assay preparation* corresponds to that in the chromatogram of the *Standard preparation*, as obtained in the *Assay*.
ACARBOSE	IMPURITIES	*USPNF Online*	Online	29-Dec-2023	1-Jan-2024	*NA*	*NA*	In *Chromatographic Purity/Analysis*: Change Result = $(r_U/r_A) \times (1/F) \times 100$ to: Result = $(r_U/r_A) \times (1/F)$
GLUCAGON	PROCESS-RELATED IMPURITIES	*USPNF Online*	Online	29-Dec-2023	1-Jan-2024	*NA*	*NA*	In *Acetic Acid in Peptides/Analysis*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	AND OTHER COMPONENTS							Change C_{SPA} = concentration of potassium acetate in each of the *Standard solutions* (mg/mL) to: C_{SPA} = concentration of potassium acetate in each of the *Standard solutions* (µg/mL) AND In *Ammonium/ Analysis*: Change C_{SAC} = concentration of ammonium chloride in each of the *Standard solutions* (mg/mL) to: *C*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								SAC= concentration of ammonium chloride in each of the *Standard solutions* (µg/mL)
ANTIBIOTICS—MICROBIAL ASSAYS	APPENDICES	*USPNF Online*	Online	29-Dec-2023	1-Jan-2024	*NA*	*NA*	In two instances in *Appendix 1* equations: Change 14.020 to: 14.022
SECOBARBITAL SODIUM	OTHER REQUIREMENTS	*USPNF Online*	Online	29-Dec-2023	1-Jan-2024	*NA*	*NA*	Change Where the label states that Secobarbital Sodium is sterile, it meets the requirements for *Sterility Tests* ?71? and for *Bacterial endotoxins* under *Secobarbital Sodium for Injection*. Where the label states that

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Secobarbital Sodium must be subjected to further processing during the preparation of injectable dosage forms, it meets the requirements for *Bacterial endotoxins* under *Secobarbital Sodium for Injection*. to: Where the label states that Secobarbital Sodium is sterile, it meets the requirements for *Sterility Tests* ?71? and the level of bacterial endotoxins is not more than

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								0.9 USP Endotoxin Units per mg of secobarbital sodium tested per *Bacterial Endotoxins Test* <85>. Where the label states that Secobarbital Sodium must be subjected to further processing during the preparation of injectable dosage forms, the level of bacterial endotoxins is not more than 0.9 USP Endotoxin Units per mg of secobarbital sodium tested per *Bacterial Endotoxins Test* <85>.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
AMOXICILLIN INTRAMAMMARY INFUSION	IDENTIFICATION	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	Change The solution obtained responds to the *Identification* test under *Amoxicillin Capsules*. to: Prepare a Standard solution of USP Amoxicillin RS in 0.1 N hydrochloric acid containing 4 mg per mL. Use within 10 minutes after preparation. Apply separately 5 µL of each solution on a thin-layer chromatographic plate coated with a 0.25-mm layer of chromatographic silica gel mixture (see *Chromatograph*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								y <621>). Place the plate in a suitable chromatographic chamber, and develop the chromatogram in a solvent system consisting of a mixture of methanol, chloroform, water, and pyridine (90:80:30:10). When the solvent front has moved about three-fourths of the length of the plate, remove the plate from the chamber, and dry with warm air for 10 minutes. Locate the spots on the plate by spraying lightly

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								with a solution of ninhydrin in alcohol containing 3 mg per mL, and dry at 110° for 15 minutes: the R_F value of the principal spot obtained from the test solution corresponds to that obtained from the Standard solution.
NORFLURANE	IMPURITIES	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *Organic Impurities*/*Table 2*: Change Line No. to: Peak Elution Order AND In *Halides*/*Figure 1*: Add label Flow Meter
CEFDINIR	IMPURITIES	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *Organic Impurities*/*Table 2*/footnote a:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
AMIKACIN SULFATE	ASSAY	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	Change 1*N*-[(*Z*)-2-(2-Aminothiazol-4-yl)-2-(hydroxyimino)acetyl]glycine. to: *N*-[(*Z*)-2-(2-Aminothiazol-4-yl)-2-(hydroxyimino)acetyl]glycine. In *Procedure*/*Analysis*: Change C_U = concentration of amikacin in the *Sample solution* (mg/mL) to: C_U = concentration of Amikacin Sulfate in the *Sample solution* (mg/mL)
DUTASTERIDE AND TAMSULOSIN	PERFORMANCE TESTS	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *Dissolution* ?711?/*Test for dutasteride*/*Tier*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
HYDROCHLORIDE CAPSULES								*2*/*Medium*: Change 10 g/L of cetyltrimethylammonium bromide and 750,000 USP units of activity/mg of pepsin, purified in 0.1 N hydrochloric acid; 900 mL to: Dissolve 10 g of cetyltrimethylammonium bromide and 1.6 g of pepsin, purified in 1000 mL of 0.1 N hydrochloric acid; 900 mL
SODIUM SALICYLATE	ADDITIONAL REQUIREMENTS	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *USP Reference Standards* ?11?: Add USP Phenol RS
CEFDINIR FOR ORAL SUSPENSION	ADDITIONAL REQUIREMENTS	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *USP Reference Standards* ?11?/USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Cefdinir Related Compound A RS: Change 413.43 to: 413.42 AND In *USP Reference Standards* ?11?/USP Cefdinir Related Compound B RS: Change $C_{14}H_{13}N_4O_4S_2$ 365.41 to: $C_{14}H_{14}N_4O_4S_2$ 366.41
COLOR AND ACHROMICITY	METHOD II: INSTRUMENTAL (QUANTITATIVE) ASSESSMENT OF COLOR AND COLOR MATCHES	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *Table 5*: Change Sum 98.809 100.000 107.307 White point 98.811 100.000 107.304 to: Sum 94.809 100.000 107.307

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
AZITHROMYCIN	IMPURITIES	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	White point 94.811 100.000 107.304 In *Organic Impurities*/*Table 2*: Change 3'-*N* -D emet hyl-3'-*N* -[(4-methylphen yl)sulfonyl]azithr omycin[m] to: 3?-*N* -{[4-(Acetylamin o)phenyl]sulfon yl}-3?-demethyl azithromycin[m] AND In *Table 2*/footnote m: Change (2*R*,3*S*,4*R*,5*R* ,8*R*,10*R*,11*R* ,12*S*,13*S*,14*R*)-13-[(2,6-Dideo xy-3-*C* -meth yl-3-*O*-methyl-?- L-*ribo*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-hexopyranosyl) oxy]-2-ethyl-3,4, 10-trihydroxy-3, 5,6,8,10,12,14- heptamethyl-11- [[3-[*N* -(4-methylpheny lsulfon yl)-*N* -methylamino]-3 ,4,6-trideoxy-ß- D-*xylo* -hexopyranosyl] oxy]-1-oxa-6-az acyclopentadec an-15-one. to: (2*R*,3*S*,4*R*,5*R* ,8*R*,10*R*,11*R* ,12*S*,13*S*,14*R*)-13-[(2,6-Dideo xy-3-*C* -meth yl-3-*O*-methyl-?- L-*ribo* -hexopyranosyl) oxy]-2-ethyl-3,4, 10-trihydroxy-3, 5,6,8,10,12,14- heptamethyl-11- [[3-[*N*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-(4-acetamidoph en ylsulf onyl)-*N* -methylamino]-3 ,4,6-trideoxy-?- D-*xylo* -hexopyranosyl] oxy]-1-oxa-6-az acyclopentadec an-15-one.
OLMESARTAN MEDOXOMIL TABLETS	PERFORMANCE TESTS	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *Dissolution* ?711?/*Test 5*/*Apparatus 2*: Change 50 rpm. Use peak vessels. to: 50 rpm. Use apex vessels.
CEFDINIR	ADDITIONAL REQUIREMENTS	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *USP Reference Standards* ?11?/USP Cefdinir Related Compound A RS: Change 413.43 to: 413.42

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
AMOXICILLIN BOLUSES	IDENTIFICATION	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	Change *Application volume*, *Developing solvent system*, *Procedure*—Proceed as directed for the *Identification* test under *Amoxicillin Tablets*. to: *Application volume*—5 µL. *Developing solvent system*—a mixture of methanol, chloroform, water, and pyridine (90:80:30:10). *Procedure*—Proceed as directed in *Thin-Layer Chromatographic Identification*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Test <201>. Dry the plate with the aid of a current of warm air for 10 minutes. Locate the spots on the plate by spraying lightly with a solution of ninhydrin in alcohol containing 3 mg per mL, and dry at 110° for 15 minutes.
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE CAPSULES	ADDITIONAL REQUIREMENTS	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *USP Reference Standards* ?11?/USP Dihydrodutasteride RS: Change *N* -[2,5-Bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5?-androst-1-ene-17?-carboxamide. to: *N*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-[2,5-Bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5?-androstane-17?-carboxamide.
Strychnine Sulfate	REAGENTS AND REFERENCE TABLES	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *Reagent Specifications*: Change CAS RN®: 60-41-3. to: CAS RN®: 60491-10-3.
MEASUREMENT OF STRUCTURAL STRENGTH OF SEMISOLIDS BY PENETROMETRY	APPARATUS	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *Figure 2*: Change 66±0.25 Ø to: 65±0.25 Ø
DICLOFENAC SODIUM AND MISOPROSTOL DELAYED-RELEASE TABLETS	PERFORMANCE TESTS	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *Dissolution* ?711?: Move *Test 2* after *Test 1*
PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS	PERFORMANCE TESTS	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *Dissolution* ?711?/*Test 2*/*Acid stage*: Change **Acid stage**

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								standard solution: (*L*/10) mg/mL of USP Pantoprazole Sodium RS from the *Standard stock solution* in *Acid stage medium*, where *L* is the label claim in mg/Tablet to: **Acid stage standard solution:** (*L*/10000) mg/mL of USP Pantoprazole Sodium RS from the *Standard stock solution* in *Acid stage medium*, where *L* is the label claim in mg/Tablet AND In *Dissolution* <711>/*Test*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								2/*Buffer stage*: Change **Buffer stage standard solution:** (*L*/1000) of USP Pantoprazole Sodium RS where *L* is the label claim in mg/Tablet to: **Buffer stage standard solution:** (*L*/1000) mg/mL of USP Pantoprazole Sodium RS from the *Standard stock solution* in *Buffer stage medium*, where *L* is the label claim in mg/Tablet
CEFDINIR CAPSULES	ADDITIONAL REQUIREMENTS	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *USP Reference Standards*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TELMISARTAN TABLETS	PERFORMANCE TESTS	*USPNF Online*	Online	27-Oct-2023	1-Nov-2023	*NA*	*NA*	?11?/USP Cefdinir Related Compound A RS: Change 413.43 to: 413.42 AND In *USP Reference Standards* ?11?/USP Cefdinir Related Compound B RS: Change $C_{14}H_{13}N_4O_4S_2$ 365.41 to: $C_{14}H_{14}N_4O_4S_2$ 366.41 In *Dissolution* ?711?/*Test 1*/*Analysis*: Change Determine the percentage of telmisartan ($C_{33}H_{30}N_4O_2$) dissolved: Result = (A_U × *C*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$_S$× V × 100)/(A_S × D × L) to: Calculate the percentage of the labeled amount of telmisartan ($C_{33}H_{30}N_4O_2$) dissolved: Result = (A_U/A_S) × C_S × V × D × (1/L) × 100 AND Change C_S = concentration of the *Standard solution* (mg/mL) to: C_S = concentration of USP Telmisartan RS in the *Standard solution* (mg/mL) AND In *Dissolution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								?711?/*Test 2*/*Analysis*: Change r_U = peak response from the *Sample solution* r_S = peak response from the *Standard solution* to: r_U = peak response of telmisartan from the *Sample solution* r_S = peak response of telmisartan from the *Standard solution* AND In *Dissolution* ?711?/*Test 3*/*Analysis*: Change C_S = concentration of the *Standard solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(mg/mL) to: C_S = concentration of USP Telmisartan RS in the *Standard solution* (mg/mL)
METHYLBENZETHONIUM CHLORIDE	ASSAY	*USPNF Online*	Online	27-Oct-2023	1-Nov-2023	*NA*	*NA*	In *Procedure/Analysis*: Change Calculate the percentage of methylbenzethonium chloride ($C_{28}H_{44}ClNO_2 \cdot H_2O$) in the portion of Methylbenzethonium Chloride taken: to: Calculate the percentage of methylbenzethonium chloride ($C_{28}H_{44}ClNO_2$) in the portion of Methylbenzethonium Chloride

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
AMOXICILLIN FOR INJECTABLE SUSPENSION	Identification	*USPNF Online*	Online	27-Oct-2023	1-Nov-2023	*NA*	*NA*	taken: Change Prepare a test solution containing the equivalent of 4 mg of amoxicillin per mL by adding 0.1 N hydrochloric acid to Amoxicillin for Injectable Suspension. Allow the solution to stand for 5 minutes before use: the solution responds to the *Identification* test under *Amoxicillin Capsules*. to: Prepare a test solution containing the equivalent of 4

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								mg of amoxicillin per mL by adding 0.1 N hydrochloric acid to Amoxicillin for Injectable Suspension. Allow the solution to stand for 5 minutes before use. Prepare a Standard solution of USP Amoxicillin RS in 0.1 N hydrochloric acid containing 4 mg per mL. Use within 10 minutes after preparation. Apply separately 5 µL of each solution on a thin-layer c hromatographic plate coated with a 0.25-mm

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								layer of chromatographic silica gel mixture (see *Chromatography* <621>). Place the plate in a suitable chromatographic chamber, and develop the chromatogram in a solvent system consisting of a mixture of methanol, chloroform, water, and pyridine (90:80:30:10). When the solvent front has moved about three-fourths of the length of the plate, remove the plate from the chamber, and dry with warm air for 10

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								minutes. Locate the spots on the plate by spraying lightly with a solution of ninhydrin in alcohol containing 3 mg per mL, and dry at 110° for 15 minutes: the R_F value of the principal spot obtained from the test solution corresponds to that obtained from the Standard solution.
OIL- AND WATER-SOLUBLE VITAMINS WITH MINERALS CAPSULES	STRENGTH	*USPNF Online*	Online	27-Oct-2023	1-Nov-2023	*NA*	*NA*	In *Vitamin A, Method 3/Analysis*: Change C_S = concentration of retinyl acetate ($C_{23}H_{32}O_2$) from USP Vitamin A RS in the *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
UREA	SPECIFIC TESTS	*USPNF Online*	Online	27-Oct-2023	1-Nov-2023	*NA*	*NA*	*solution* (?g/mL) to: C_S = concentration of retinyl acetate ($C_{22}H_{32}O_2$) from USP Vitamin A RS in the *Standard solution* (?g/mL) In *Alcohol-Insoluble Matter*/*Sample solution*: Change 100 mg/mL of Urea dissolved in warm alcohol to: Dissolve 5.0 g of Urea in 50 mL of warm alcohol. AND In *Alcohol-Insoluble Matter*/*Analysis*: Change If any insoluble residue remains, pass

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the *Sample solution* through a tared filter, wash the residue and the filter with 20 mL of warm alcohol per 50 mL of *Sample solution*, and dry at 105° for 1 h. to: If any insoluble residue remains, pass the *Sample solution* through a tared filter, wash the residue and the filter with 20 mL of warm alcohol, and dry at 105° for 1 h.
TELMISARTAN ASSAY TABLETS		*USPNF Online*	Online	27-Oct-2023	1-Nov-2023	*NA*	*NA*	In *Procedure*/*System suitability*/*Suitability requirements*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change **Resolution:** NLT 3 between telmisartan and telmisartan related compound A **Tailing factor:** NMT 2.0 for the telmisartan peak **Capacity factor:** NLT 1.5 **Relative standard deviation:** NMT 2.0% to: **Resolution:** NLT 3 between telmisartan and telmisartan related compound A **Tailing factor:** NMT 2.0 for telmisartan **Relative standard deviation:** NMT

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PARTICLE SIZE ANALYSIS BY DYNAMIC LIGHT SCATTERING	GLOSSARY	*USPNF Online*	Online	27-Oct-2023	1-May-2024	*NA*	*NA*	2.0% for telmisartan In *Average particle diameter*: Change expressed in nanometers. to: expressed in meters. AND In *Viscosity*: Change in millipascal-seconds (mPa?s). to: in pascal-seconds (Pa?s).
OIL-SOLUBLE VITAMINS CAPSULES	STRENGTH	*USPNF Online*	Online	27-Oct-2023	1-Nov-2023	*NA*	*NA*	In *Vitamin A, Method 3/Analysis*: Change C_S = concentration of retinyl acetate ($C_{23}H_{32}O_2$) from USP Vitamin A RS in the *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution (?g/mL) to: C_S = concentration of retinyl acetate ($C_{22}H_{32}O_2$) from USP Vitamin A RS in the *Standard solution* (?g/mL)
PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS	ASSAY	*USPNF Online*	Online	27-Oct-2023	1-Nov-2023	*NA*	*NA*	In *Procedure*/*System suitability*/*Tailing factor*: Change NMT 2.0, *System suitability solution* to: NMT 2.0 for pantoprazole, *System suitability solution*
TAMSULOSIN HYDROCHLORIDE CAPSULES	IMPURITIES	*USPNF Online*	Online	29-Sep-2023	1-Oct-2023	*NA*	*NA*	In *Organic Impurities*/*System suitability*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Sample: *Standard solution* [Note—The relative retention times for methoxy tamsulosin, tamsulosin, ethoxyphenoxy ethyl bromide, and desethoxy tamsulosin are 0.73, 1.00, 1.80, and 2.80, respectively.] **Suitability requirements** **Tailing factor:** NMT 2.0 **Relative standard deviation:** NMT 5.0% **Signal-to-noise ratio:** NLT 10 to: **Samples:** *Standard solution* and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Sensitivity solution [Note—The relative retention times for methoxy tamsulosin, tamsulosin, ethoxyphenoxy ethyl bromide, and desethoxy tamsulosin are 0.73, 1.00, 1.80, and 2.80, respectively.] **Suitability requirements** **Tailing factor:** NMT 2.0, *Standard solution* **Relative standard deviation:** NMT 5.0%, *Standard solution* **Signal-to-noise ratio:** NLT 10, *Sensitivity solution*

Pagination

- Current page 1
- Page 2
- Page 3
- Page 4
- Page 5
- Page 6
- Page 7
- Page 8
- Page 9
- …
- Next page Next ›
- Last page Last »